Diabetes with Cardiovascular and Kidney Complications

Learning Objectives

Recall current guidelines for the management of people with type 2 diabetes and chronic kidney disease (CKD).
Identify options to reduce cardiovascular (CV) risk in people with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD).
Summarize the evidence supporting the use of sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment for patients with heart failure with reduced ejection fraction (HFrEF).

Faculty

Jennifer B. Green, MD
Professor of Medicine, Endocrinology, Metabolism, and Nutrition
Duke University School of Medicine
Duke Clinical Research Institute

Summary


Availability:	On-Demand


Cost:	FREE


Credit Offered:	No Credit Offered

Create Account